---
stable_id: R-HSA-2559583
display_name: Cellular Senescence
species: Homo sapiens
summary: Cellular senescence involves irreversible growth arrest accompanied by phenotypic
  changes such as enlarged morphology, reorganization of chromatin through formation
  of senescence-associated heterochromatic foci (SAHF), and changes in gene expression
  that result in secretion of a number of proteins that alter local tissue environment,
  known as senescence-associated secretory phenotype (SASP).<br><br>Senescence is
  considered to be a cancer protective mechanism and is also involved in aging. Senescent
  cells accumulate in aged tissues (reviewed by Campisi 1997 and Lopez-Otin 2013),
  which may be due to an increased senescence rate and/or decrease in the rate of
  clearance of senescent cells. In a mouse model of accelerated aging, clearance of
  senescent cells delays the onset of age-related phenotypes (Baker et al. 2011).<p>Cellular
  senescence can be triggered by the aberrant activation of oncogenes or loss-of-function
  of tumor suppressor genes, and this type of senescence is known as the oncogene-induced
  senescence, with RAS signaling-induced senescence being the best studied. Oxidative
  stress, which may or may not be caused by oncogenic RAS signaling, can also trigger
  senescence. Finally,  the cellular senescence program can be initiated by DNA damage,
  which may be caused by reactive oxygen species (ROS) during oxidative stress, and
  by telomere shortening caused by replicative exhaustion which may be due to oncogenic
  signaling. The senescent phenotype was first reported by Hayflick and Moorhead in
  1961, when they proposed replicative senescence as a mechanism responsible for the
  cessation of mitotic activity and morphological changes that occur in human somatic
  diploid cell strains as a consequence of serial passaging, preventing the continuous
  culture of untransformed cells-the Hayflick limit (Hayflick and Moorhead 1961).<p>
  Secreted proteins that constitute the senescence-associated secretory phenotype
  (SASP), also known as the senescence messaging secretome (SMS), include inflammatory
  and immune-modulatory cytokines, growth factors, shed cell surface molecules and
  survival factors. The SASP profile is not significantly affected by the type of
  senescence trigger or the cell type (Coppe et al. 2008), but the persistent DNA
  damage may be a deciding SASP initiator (Rodier et al. 2009). SASP components function
  in an autocrine manner, reinforcing the senescent phenotype (Kuilman et al. 2008,
  Acosta et al. 2008), and in the paracrine manner, where they may promote epithelial-to-mesenchymal
  transition (EMT) and malignancy in the nearby premalignant or malignant cells (Coppe
  et al. 2008).<p>Senescent cells may remain viable for years, such as senescent melanocytes
  of moles and nevi, or they can be removed by phagocytic cells. The standard marker
  for immunohistochemical detection of senescent cells is senescence-associated beta-galactosidase
  (SA-beta-Gal), a lysosomal enzyme that is not required for senescence.<p>For reviews
  of this topic, please refer to Collado et al. 2007, Adams 2009, Kuilman et al. 2010.
  For a review of differential gene expression between senescent and immortalized
  cells, please refer to Fridman and Tainsky 2008.
---

# Cellular Senescence
**Reactome ID:** [R-HSA-2559583](https://reactome.org/content/detail/R-HSA-2559583)
**Species:** Homo sapiens

## Summary

Cellular senescence involves irreversible growth arrest accompanied by phenotypic changes such as enlarged morphology, reorganization of chromatin through formation of senescence-associated heterochromatic foci (SAHF), and changes in gene expression that result in secretion of a number of proteins that alter local tissue environment, known as senescence-associated secretory phenotype (SASP).<br><br>Senescence is considered to be a cancer protective mechanism and is also involved in aging. Senescent cells accumulate in aged tissues (reviewed by Campisi 1997 and Lopez-Otin 2013), which may be due to an increased senescence rate and/or decrease in the rate of clearance of senescent cells. In a mouse model of accelerated aging, clearance of senescent cells delays the onset of age-related phenotypes (Baker et al. 2011).<p>Cellular senescence can be triggered by the aberrant activation of oncogenes or loss-of-function of tumor suppressor genes, and this type of senescence is known as the oncogene-induced senescence, with RAS signaling-induced senescence being the best studied. Oxidative stress, which may or may not be caused by oncogenic RAS signaling, can also trigger senescence. Finally,  the cellular senescence program can be initiated by DNA damage, which may be caused by reactive oxygen species (ROS) during oxidative stress, and by telomere shortening caused by replicative exhaustion which may be due to oncogenic signaling. The senescent phenotype was first reported by Hayflick and Moorhead in 1961, when they proposed replicative senescence as a mechanism responsible for the cessation of mitotic activity and morphological changes that occur in human somatic diploid cell strains as a consequence of serial passaging, preventing the continuous culture of untransformed cells-the Hayflick limit (Hayflick and Moorhead 1961).<p> Secreted proteins that constitute the senescence-associated secretory phenotype (SASP), also known as the senescence messaging secretome (SMS), include inflammatory and immune-modulatory cytokines, growth factors, shed cell surface molecules and survival factors. The SASP profile is not significantly affected by the type of senescence trigger or the cell type (Coppe et al. 2008), but the persistent DNA damage may be a deciding SASP initiator (Rodier et al. 2009). SASP components function in an autocrine manner, reinforcing the senescent phenotype (Kuilman et al. 2008, Acosta et al. 2008), and in the paracrine manner, where they may promote epithelial-to-mesenchymal transition (EMT) and malignancy in the nearby premalignant or malignant cells (Coppe et al. 2008).<p>Senescent cells may remain viable for years, such as senescent melanocytes of moles and nevi, or they can be removed by phagocytic cells. The standard marker for immunohistochemical detection of senescent cells is senescence-associated beta-galactosidase (SA-beta-Gal), a lysosomal enzyme that is not required for senescence.<p>For reviews of this topic, please refer to Collado et al. 2007, Adams 2009, Kuilman et al. 2010. For a review of differential gene expression between senescent and immortalized cells, please refer to Fridman and Tainsky 2008.
